Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mitchell Revill"'
Autor:
Maximilian W. Schenk, Sam Humphrey, A. S. Md Mukarram Hossain, Mitchell Revill, Sarah Pearsall, Alice Lallo, Stewart Brown, Samuel Bratt, Melanie Galvin, Tine Descamps, Cong Zhou, Simon P. Pearce, Lynsey Priest, Michelle Greenhalgh, Anshuman Chaturvedi, Alastair Kerr, Fiona Blackhall, Caroline Dive, Kristopher K. Frese
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The emergence of acquired resistance to standard platinum-etoposide chemotherapy in small cell lung cancer (SCLC) is a common event. Here, the authors using paired pre-treatment and post-chemotherapy circulating tumour cell patient-derived explant (C
Externí odkaz:
https://doaj.org/article/a99beedee95f4504bd782063edbc7711
Autor:
Francesca Trapani, Matthew G Krebs, Alastair R.W. Kerr, Adi F. Gazdar, Fiona H Blackhall, Kristopher K. Frese, William Rowe, Nicole Simms, Simon P. Pearce, Laura Booth, Mitchell Revill, Lynsey Priest, Caroline Dive, Derrick Morgan, Luc Girard, Louise Carter, Marek Dynowski, Melanie Galvin, Ruth A Stoney, Kathryn Simpson, Mathew Carter, Thomas Helps, Natalie Cook, Daisuke Nonaka, Alessia Catozzi, Sam Humphrey
Publikováno v:
Nature Cancer. 1:437-451
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18cb61eecfa32e8c5293a0e42010918b
https://doi.org/10.1038/s43018-020-0046-2
https://doi.org/10.1038/s43018-020-0046-2
Autor:
Alessia Catozzi, Mitchell Revill, Jordan Roebuck, Sam Humphrey, Melanie Galvin, Fiona Blackhall, Kathryn Simpson, Alastair Kerr, Kristopher Frese, Caroline Dive
Publikováno v:
Cancer Research. 82:2360-2360
SCLC is an aggressive neuroendocrine (NE) cancer with a 7% 5-year survival rate. SCLC is treated as a clinically homogenous disease, but evidence of its intra- and inter-tumor heterogeneity is increasing. This is partly attributed to expression of ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b354e3408b52963b00cf12aaea399bc5
https://doi.org/10.1158/1538-7445.am2022-2360
https://doi.org/10.1158/1538-7445.am2022-2360
Autor:
Kristopher K. Frese, Derrick Morgan, Sam Humphrey, Mitchell Revill, Kathryn Simpson, Sarah M. Pearsall, Mathew Carter, Caroline Dive, Fiona H Blackhall, Lynsey Priest, Alistair Kerr, Melanie Galvin
Publikováno v:
Journal of Thoracic Oncology
Introduction Recent consensus defines four SCLC subtypes on the basis of transcription factor expression: ASCL1, NEUROD1, POU2F3, and YAP1. The rare YAP1 subtype is associated with “neuroendocrine (NE)-low” cells among SCLC cell lines and patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96aa2476adec5c74c966762ddb18dbb5
https://pubmed.ncbi.nlm.nih.gov/32721553
https://pubmed.ncbi.nlm.nih.gov/32721553
Autor:
Derrick Morgan, Lynsey Priest, Stewart Brown, Kristopher K. Frese, Fiona H Blackhall, Mitchell Revill, Caroline Dive, Sheila K. Singh, Melanie Galvin, Maria Peiris-Pagès, Kathryn Simpson, Mathew Carter
Publikováno v:
Cancer Research. 81:2874-2874
Small cell lung cancer (SCLC) accounts for about 13% of all malignant lung tumors and is characterized by an extremely low survival rate and widespread early dissemination. Over two-thirds of SCLC patients are diagnosed with metastases in multiple or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79bc0b678ebd7586f0caedd214c02884
https://doi.org/10.1158/1538-7445.am2021-2874
https://doi.org/10.1158/1538-7445.am2021-2874
Abstract 2436: Heterogeneity of neurogenic transcription factor expression in small cell lung cancer
Autor:
Mitchell Revill, Kristopher K. Frese, Fiona H Blackhall, Kathryn Simpson, Alessia Catozzi, Caroline Dive
Publikováno v:
Cancer Research. 81:2436-2436
SCLC is an aggressive neuroendocrine (NE) cancer with a 7% 5-year survival rate. Molecular characterization of this disease has lagged behind other cancer types and standard of care treatment has remained largely unchanged for over three decades. SCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8cfd701f5799d2af5eb5b4301ea4e0
https://doi.org/10.1158/1538-7445.am2021-2436
https://doi.org/10.1158/1538-7445.am2021-2436
Autor:
Stephen Green, Armelle Logie, Nichola Whalley, Nicola Curtis, Kate Byth, Haihong Zhong, Clare Murray, Mike Firth, Lorna Hopcroft, Lorraine Mooney, Filippos Michopoulos, Paul D. Smith, Amanda Benjamin, Mitchell Revill, Susan E. Critchlow
Publikováno v:
Oncotarget
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b83ba3dacb5ced8e0814ba2003af3da
https://doi.org/10.18632/oncotarget.18215
https://doi.org/10.18632/oncotarget.18215
Autor:
Anna Staniszewska, Paul Lyne, Lyndsey Hanson, Linda K. Buckett, Claire Rooney, Sanjay K. Pandey, David C. Blakey, Kevin Hudson, Alexey S. Revenko, Sarah Ross, A. Robert MacLeod, Mitchell Revill, Brett P. Monia, Stephanie Klein, Michael Zinda, Rebecca Ellston, Nicky Whalley
Publikováno v:
Science Translational Medicine. 9
Activating mutations in KRAS underlie the pathogenesis of up to 20% of human tumors, and KRAS is one of the most frequently mutated genes in cancer. Developing therapeutics to block KRAS activity has proven difficult, and no direct inhibitor of KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597423bc8d0d31f7615064de2a3e139b
https://doi.org/10.1126/scitranslmed.aal5253
https://doi.org/10.1126/scitranslmed.aal5253
Autor:
Brett P. Monia, Sarah Ross, Mitchell Revill, Stephanie Klein, Alexey S. Revenko, Rebecca Ellston, Allan R. MacLeod, Lyndsey Hanson, David C. Blakey, Linda K. Buckett, Paul Lyne, Chris May, Kevin Hudson, Sanjay K. Pandey
Publikováno v:
Molecular Cancer Therapeutics. 14:PR12-PR12
KRAS is one of the most frequently mutated genes in cancer and its activation is thought to underlie the pathogenesis of up to 30% of all human tumors. However, to date KRAS has proven difficult to target with traditional pharmacologic approaches. An
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abac74d500efb5beb798ddae91f25ac1
https://doi.org/10.1158/1535-7163.targ-15-pr12
https://doi.org/10.1158/1535-7163.targ-15-pr12
Autor:
Liang Xie, Jingchuan Zhang, Lorraine Mooney, Nicola Curtis, De-Hua Yu, Haihong Zhong, Clare Murray, Paul D. Smith, Nicky Whalley, Armelle Logie, Lorna Hopcroft, Susan E. Critchlow, Mitchell Revill
Publikováno v:
Cancer Research. 72:3224-3224
Introduction - The metabolic phenotype of tumours (relative to most normal tissues) is shifted from oxidative phosphorylation to aerobic (Warburg Effect) or anaerobic glycolysis. This enables tumours to meet their energetic and biosynthetic demands e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3f12818713018ca5d37b3eee4c36a40
https://doi.org/10.1158/1538-7445.am2012-3224
https://doi.org/10.1158/1538-7445.am2012-3224